secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-10-10T23:59:59+00:00
Accession:  0001213900-23-081286
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics updates corporate presentation as of October 2023; no specific new data disclosed.
--------------------------------------------------------------------------------

- Furnished updated corporate presentation under Regulation FD; presentation dated October 2023.
- Presentation cover slide states Briquilimab is investigational and not approved for any indication.
- No financial, clinical, or operational metrics from the presentation are included in the filing.
- Company disclaims obligation to update the presentation material in the future.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023081286/0001213900-23-081286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023081286/ea186520-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-081286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer